International Psoriasis Council

Advancing Knowledge. Improving Care.

Amy

Paller

,

MS, MD

Walter J. Hamlin Professor and Chair
Northwestern University Feinberg Medical School
Chicago
,
Illinois
,
United States
Councilor Since: March 1, 2010
IPC Board Member
Dr. Amy Paller is the Walter J. Hamlin Professor and Chair of Dermatology, Professor of Pediatrics, and Principal Investigator of the NIH-funded Skin Biology and Diseases Resource-based Center at Northwestern University’s Feinberg School of Medicine. She received her undergraduate and graduate degrees from Brown University and her medical degree from Stanford University. Dr. Paller completed residency training in Pediatrics and Dermatology at Northwestern University and her postdoctoral research fellowship at the University of North Carolina. An author of >750 original publications, Dr. Paller is an NIH-funded investigator conducting laboratory-based and clinical investigations related to psoriasis. Dr. Paller has led international epidemiological studies on psoriasis and atopic dermatitis, developed new tools to measure patient-related outcomes in pediatric inflammatory skin disease, and focused on psoriasis research on obesity, cutaneous innervation, and new nanotechnology-based treatment approaches. She has been the lead investigator on landmark trials in pediatric skin disease, including the first TNF inhibitor and the first IL-17 inhibitor for children with psoriasis, as well as several new topical and systemic therapies for atopic dermatitis. She has served on the Medical Advisory Board (now Emeritus) and received the Excellence in Leadership Award from the National Psoriasis Foundation (NPF). Dr. Paller has been an active IPC Councilor since 2010 and is now a member of IPC’s Board of Directors. She has served as Chair of the National Eczema Association’s Scientific and Medical Advisory Council and was co-founder and inaugural President of the International Eczema Council (IEC). She has also been President of the Society for Investigative Dermatology (SID), the Society for Pediatric Dermatology (SPD), the Pediatric Dermatology Research Alliance (PeDRA), the Women’s Dermatological Society (WDS), the International Society of Pediatric Dermatology (ISPD), and the American Dermatological Association (ADA). She has served on the Board of many national and international organizations, including the American Academy of Dermatology (AAD) and the American Board of Dermatology (ABD), and on the editorial boards of leading journals, including, currently, as Section Editor of the Journal of Investigative Dermatology (JID). She has written several textbooks, including the leading textbook for pediatric dermatology, Hurwitz Clinical Pediatric Dermatology.
Last Updated:
02/19/2026

Areas of Interest

Bench Research, Nanoconstruct Gene-Regulatory Treatments for Psoriasis, Neuroimmunology and Keratinocyte Cross-Talk in Psoriasis, Obesity-Related Impacts on Psoriasis Severity and Treatment Response, Epidemiologic Studies, Clinical Trials, Patient-Reported Outcomes Research, Pediatric Itch Assessment Tools, PROMIS Itch Questionnaire–Childhood, Stigma Measurement Tools, Pediatric Dermatology

IPC Committees / Groups

Board Member, Pediatric Global Burden Task Force, Pediatric Psoriasis Working Group

Languages Spoken

English

Involvement with Other Organization(s)

Dr. Paller participates in the National Psoriasis Foundation’s (NPF) activities and was previously an NPF medical Board Member.

What's New

Videos Now Available from the IPC Symposium at SID Chicago

Did you miss the IPC symposium at the 83rd Society for Investigative Dermatology (SID) Annual Meeting? Select session videos are now available. The Arc of Disease Control in Psoriasis: Early Interception – Deep Pathway Blockade – Treatment Failure covered early intervention strategies, treatment selection, immune pathway targeting, PsA prevention, clinical escape, and real-world cases that inform long-term psoriasis care.

WATCH NOW

Wednesday, June 17, 2026

Take Ten: Mio Nakamura – Psoriasis and Mental Health

Depression affects approximately 20% of patients with psoriasis, five times the rate seen in the general population. IPC Jr. Councilor Mio Nakamura, MD, MS, FAAD, walks through the bidirectional relationship between psoriasis and depression, the shared inflammatory pathways driving both conditions, and practical guidance on screening and incorporating multidisciplinary mental health support into psoriasis management.

WATCH NOW

Thursday, June 11, 2026